TGFB1 and neoplasm: Targeting inhibition of TGF‐β via coculturing with a TGF‐β kinase inhibitor, galunisertib, or knocking out TGF‐β by CRISPR‐Cas9 prevented NK cell dysfunction as well as immune evasion by tumor cells ex vivo.144